| Project/Area Number |
22790694
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Circulatory organs internal medicine
|
|---|
| Research Institution | Tokyo University of Pharmacy and Life Science (2011)
Tokyo Medical and Dental University (2010) |
|---|
Principal Investigator |
SATO Kengo 東京薬科大学, 生命科学部心血管医科学研究室, 助教 (70549930)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 動脈硬化 / 血管作動性物質 / 単球 / マクロファージ / salusin-β / radioimmunoassay / ELISA / サイトカイン |
|---|
| Research Abstract |
Salusin-β is released from human monocytes/macrophages suggest a possible autocrine/paracrine role in the development and progression of atherosclerosis. Inflammatory cytokines induced secretion was not the result of preprosalusin gene induction, but might have been caused by increased intracellular processing of prosalusin. Our results implicate that salusin-β could be a novel therapeutic target for the prevention of atherosclerosis. It has been impossible to accurately measure plasma salusin-β levels by radioimmunoassay, therefore, we have established a specific enzyme-linked immunosorbent assay(ELISA) suitable for detection of immunoreactive salusin-β in human plasma. The salusin-β-like immunoreactivity in normal human plasma was about 1 nmol/L. Prospective studies of salusin-βt hat examine relationships with plasma salusin-βlevels and severity of atherosclerosis by ELISA and the usefulness of salusin-β as a biomarker for atherosclerosis.
|
